During the last three months, 4 analysts shared their evaluations of Haemonetics (NYSE:HAE), revealing diverse outlooks from bullish to bearish.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $110.5, a high estimate of $125.00, and a low estimate of $105.00. Witnessing a positive shift, the current average has risen by 2.0% from the previous average price target of $108.33.

Decoding Analyst Ratings: A Detailed...